The mechanisms by which Parkinson disease-linked parkin confers neuroprotection of human dopamine cells remain elusive. We hypothesized that its cysteines mediate multiple anti-oxidant effects in the midbrain. By studying >60 control specimens, we found that in adult human brainbut not in skeletal muscle-parkin is mostly aggregated and insoluble due to oxidative modifications, such as at C253. In vitro, parkin's oxidation directly reduces hydrogen peroxide (H2O2) to water. In parkin-deficient human brain, H2O2 concentrations are elevated. In dopamine toxicity studies, wild-type parkin -but not disease-associated mutants-prevents neural death by lowering H2O2 and sequestering radicals within insoluble aggregates. Parkin conjugates dopamine metabolites at the human-specific residue C95 and augments melanin formation in vitro. Using epitope-mapped antibodies, we found that in adult Substantia nigra neurons parkin localizes to neuromelanin within LAMP-3/CD63-positive lysosomes. We conclude that parkin's own oxidation, previously considered a loss-of-function event, underlies three neuroprotective effects in adult midbrain: its cysteines participate in H2O2 reduction, dopamine radical conjugation and the formation of neuromelanin.
INTRODUCTION
parkin to rising concentrations of H2O2, DA, the DA metabolite aminochrome, and mitochondrial toxins, e.g., CCCP and rotenone, generated high Mr smears and progressive insolubility ( Fig. 2a; Extended Data Fig. 4a-c) ). Some of these biochemical changes were reversible, as seen for insoluble, H2O2-oxidized r-parkin upon exposure to DTT (Fig. 2b) . Others could not be reduced, such as when irreversible, covalent modifications had occurred (Extended Data Fig. 4a-c; data not shown). Blocking access to parkin's thiols prevented its oxidation (see below). Demonstrating sensitivity to bi-directional redox changes, exposure of native r-parkin to excess DTT also rendered it insoluble (Extended Data Figs. 3,4d ).
Redox stress alters parkin's structure
The progressive insolubility of parkin with increasing oxidative stress in vitro and in vivo suggested that the nascent protein responds to redox alterations with structural change(s). We tested this by dynamic light scattering (DLS) and far-UV-circular dichroism (CD). When we monitored r-parkin during spontaneous oxidization using DLS (Extended Data Fig. 4g ), we observed a shift in r-parkin's hydrodynamic diameter from 5.1 nm, representing a folded monomer at the start, to multiple peaks with larger diameters 5 hrs later; the latter indicated multimer formation. These oxidation-induced changes were reversible by DTT.
To further monitor structural changes, we analyzed the effects of spontaneous oxidation in naïve and H2O2-treated r-parkin by CD ( Fig. 2c,d; Extended Data Fig. 4e,f) . At the start, soluble fractions contained both α-helically ordered as well as unstructured proteins ( Fig. 2b;  Extended Data Fig. 4e ). After five days, r-parkin preparations were centrifuged, and soluble and insoluble fractions re-analyzed ( Fig. 2d; Extended Data Fig. 4f ). There, we found a marked shift by CD from an α-helically ordered (and unstructured) content to increased amounts of bpleated sheet-positive r-parkin in insoluble, aggregate-rich fractions. This shift was more pronounced in H2O2-oxidized protein preparations (Extended Data Fig. 4f ).
Hydrogen peroxide modifies parkin at multiple cysteines
To further confirm that oxidation of parkin cysteines led to redox state change and insolubility, we used liquid chromatography-based mass spectrometry (LC-MS/MS). We employed a serial IAA-DTT-NEM fingerprinting approach to differentiate reduced thiols (tagged by IAA) from reversibly oxidized thiols (reduced by DTT and then tagged by N-ethylmaleimide (NEM)). We first asked whether oxidation of r-parkin led to changes in thiol redox state regardless of solubility. At higher H2O2 concentrations, 32 of 35 cysteines (91.4%) were identified; >93.8 % were found modified at least once. Using Scaffold PTM-software, we recorded the anticipated rise in NEM-tagged cysteines following H2O2 treatment (Extended Data Fig. 4h ). Oxidative modifications were identified at parkin's RING domains and at non-RING-based cysteines. Total cysteine modifications were quantified by MaxQuant software 18 . As shown in Fig. 2e , there was a significant loss of IAA signals for r-parkin's cysteines in H2O2-treated samples (P=0.0016), reflecting a decrease in reduced thiols.
In turn, when comparing cysteine oxidation in soluble vs. insoluble fractions of both untreated and oxidized r-parkin, IAA signals (i.e., free thiols) were significantly reduced in the pellets (P<0.0001; Fig. 2f ). Modifications at other residues, e.g., methionines, did not correlate with r-parkin insolubility (not shown). In these studies, residue C253 (RING1 domain) was frequently detected as oxidized. These results established that H2O2-induced oxidation of cysteine-based thiols conferred r-parkin's insolubility.
We next examined whether these thiol oxidations also occur in human brain-derived parkin by LC-MS/MS. Here, we mapped cysteines in reduced and oxidized states for the 52.5 kDa monomer purified from cortex specimens of neurological controls. The latter included irreversible oxidation events, such as to sulfonic acid at C253 ( Fig. 2g-i) and C95 (Fig. 2j,k) , as well as reversible ones, e.g., at C253, detected in insoluble parkin (see Extended Data Table 1 ).
Parkin reduces hydrogen peroxide to water
Redox reactions transfer oxygen, electrons and H + between the reactants. We therefore asked whether parkin's oxidation led to H2O2 reduction ( Fig. 3; Extended Data Fig. 5a-f) . Indeed, we found that r-parkin directly lowered H2O2 levels in a time-and concentration-dependent manner ( Fig. 3a; Extended Data Fig. 5c ). This reaction (e.g., 2R-SH+H2O2àR-S-S-R+2H2O) was dependent on thiol integrity, because pre-treatment with IAA abolished it (Fig. 3b) . Parkin's reducing capacity was confirmed in parallel studies employing a different H2O2 assay & .
We next examined the reducing capacities of other proteins, e.g., r-DJ-1, a C-terminal RING2 peptide (r-parkin321C), and two ARPD-linked mutants, p.G328E and p.C431F ( Fig. 3c-d , Extended Data Fig. 5d-f ). There, r-DJ-1 and r-parkin321C showed negligible H2O2-reduction, and the point mutants conferred less activity than wild-type r-parkin ( Fig. 3c; Extended Data  Fig. 5d,e ). These reducing effects correlated with r-parkin's own oxidation, as revealed by SDS-PAGE immediately after H2O2 exposure ( Fig. 3d) . We speculated that this activity by r-parkin was dependent on reactive thiol content. We tested this using the Ellman's reagent. There, wildtype r-parkin, r-parkin321C and r-DJ-1 showed the predicted number of reactive thiols, whereas the point mutants p.C431F and p.G328E had fewer accessible thiols ( Fig. 3e) . As predicted, we recorded a linear correlation between thiol molar equivalencies and H2O2-reducing capacities ( Fig. 3f) .
Hydrogen peroxide is elevated in parkin-deficient brain
To determine whether parkin oxidation conferred ROS reduction in adult brain, we quantified H2O2 concentration in cortices from human ARPD subjects and age-, PMI-, ethnicity-and brain region-matched control specimens (n=4 each) 1, 19 . There, we found a significant elevation in H2O2 concentrations in parkin-deficient brain lysates (P<0.05; Fig. 3g ). Of note, in specimens of non-PRKN-linked cases with parkinsonism, H2O2 levels were similar to those of age-matched controls ( Fig. 1l ). We concluded that parkin contributes to redox homeostasis in human brain. In related mouse experiments, we identified that parkin's regulation of neural H2O2 occurs in the cytosol & .
Parkin prevents dopamine toxicity by lowering hydrogen peroxide
To explore its selective neuroprotection, we revisited the role of parkin in DA-induced toxicity 13 . We first tested its redox-related functions in human neuroblastoma M17 cells. Here, wild-type parkin, but not ARPD mutants p.G328E and p.C341F, protected cells from rising DA levels ( Fig.  4a; Extended Data Fig. 6a ). Moreover, DA-exposure resulted in a significant rise in H2O2 concentrations, which wild-type -but not mutant-parkin reversed (Fig. 4b) . These ex vivo results validated our in vitro and in vivo findings ( Fig. 3 ). In stable M17 cells, protection from DA toxicity paralleled PRKN expression levels ( Fig. 4c) ; approximately 4 ng neutralized each µM of DA. Neuroprotection also correlated with parkin's own oxidation and progressive insolubility. Importantly, these modifications were not reducible by DTT ( Fig. 4d,e ), indicating irreversible thiol changes, which we reasoned were due to covalent DA adduct formation 13 .
Parkin binds dopamine radicals at cysteine 95
We asked whether parkin directly aided in the neutralization of DA through conjugation at specific residues 14 . Indeed, full-length r-parkin bound DA and aminochrome adducts, as detected for example by nitro-blue-tetrazolium staining after aminochrome exposure ( Fig. 4f ; and data not shown). Using LC-MS/MS to map these modifications, we identified several aminochrome, DA and indole-5,6-quinone adduct-carrying peptides specific to treated r-parkin (Extended Data Fig. 6c,d) . Intriguingly, the most frequently modified residue was C95, a primate sequencespecific cysteine ( Fig. 4g; Extended Data Fig. 6c ).
Parkin augments melanin formation
Given the dynamic associations between r-parkin, DA exposure, RES conjugation and aggregate formation, we tested whether these influenced melanin formation in vitro. Polymerization of DA into melanin occurs in a spontaneous, oxidation-dependent manner via intermediates, such as indole-5,6-quinone, and is blocked by glutathione 10, 20 Wild-type parkin and two point mutants, p.C431F and p.G328E, all augmented melanin formation in a time-and concentration-dependent manner ( Fig. 4h; Extended Data Fig. 6b ). We next sought to validate a role for parkin in melanin formation in vivo.
Parkin colocalizes with neuromelanin in adult S. nigra neurons
To visualize parkin's subcellular localization in adult brain, we carried out routine microscopy studies using newly developed, monoclonal antibodies to human parkin; these had been epitopemapped and validated regarding their specificity (e.g., Extended Data Fig. 7) . When staining serial sections of midbrains from control individuals, three antibodies revealed intense, granular parkin staining in the cytoplasm of pigmented neurons from adults (age >55 years), albeit at varying intensity levels amongst them (clones-D, -E and -G; Extended Data Fig.8a) . We counted anti-parkin reactivity in >83% of anti-tyrosine hydroxylase-positive cells and in many non-pigmented neurons of the midbrain and cortex (Extended Data Fig. 8b,c) .
By immunohistochemistry, in S. nigra neurons anti-parkin signals heavily overlapped with neuromelanin pigment (Extended Data Fig 8d) . Sections from individuals with parkinsonism (not linked to PRKN mutations) showed the same anti-parkin reactivities in surviving neurons and overlapping with extracellular pigment following neuronal degeneration. We found weaker anti-parkin reactivity when examining S. nigra sections of younger subjects (<33 years), which matched their paucity in neuromelanin content (Extended Data Fig. 8d,e ).
Parkin localizes to LAMP-3 + -lysosomes within nigral neurons
In screening organelle markers by immunohistochemistry, we detected highly similar staining between antibodies to parkin and lysosome-associated protein-3 (LAMP-3/CD63) reactivities (Extended Data Fig. 8f ). Antibodies to LC3B -but no mitochondrial antigens (e.g., MnSOD, VDAC)-generated much less signal overlap (not shown). Because neuromelanin granules are thought to arise within non-degradative lysosomes 21 , we carried out immunofluorescence microscopy. We found that both anti-parkin and anti-LAMP-3 antibodies strongly co-labelled with pigmented granules ( Fig. 4i) . Of note, LAMP homologues have been shown to promote long term storage of melanin in human keratinocytes 22 ; moreover, variants at the LAMP-3 locus have recently been linked to PD susceptibility 23 .
Using confocal microscopy, we demonstrated that in adult midbrain sections anti-parkin signals and neuromelanin granules were frequently surrounded by anti-LAMP-3 reactivity ( Fig.  4j) . We concluded that parkin metabolism is likely associated with LAMP-3-mediatedsequestration of DA radicals in the S. nigra of human midbrain.
DISCUSSION
We identified a heretofore unrecognized role for parkin in redox homeostasis of human brain. To date, only one other protein reportedly has a similar duality in functions (i.e., ubiquitylation and redox biology), namely the sensitive-to-apoptosis gene product, SAG (aka RBX2/ROC2/RNF7) 24 . Our work establishes that parkin's progressive insolubility in human brain, first described in the cortex by Pawlyk et al. 17 , is due to oxidative modifications during normal ageing ( Fig. 1, 2d -k; Extended Data Table 1 ). Unlike in adult brain, where parkin is mostly insoluble after the fourth decade, in the human spinal cord and aged skeletal muscle ~50% of detectable parkin remains soluble. In all other aged mammals we examined, brain parkin remains soluble to an even greater degree ( Fig. 1i ; Extended Data Fig. 1 .e,f). Theoretically, other modifications (e.g., phosphorylation 25 ) could also alter parkin's solubility.
Heretofore, parkin oxidation in cells has been interpreted as a 'loss-of-its-function' in vivo. In contrast, we posit that parkin's post-translational oxidation, related aggregate formation, and translocation into lysosomes all reflect its physiological function to maintain redox balance. Ubiquitylation and redox stabilization may not be mutually exclusive. Low concentrations of pro-oxidants have been shown to initiate parkin's ubiquitin ligase activity in vitro 15 , which we confirmed & .
The cellular thiol network is critical in DA cell health 26 . As summarized in Extended Data Fig. 9 , through its oxidation we postulate that parkin neutralizes ROS (e.g., H2O2 to water; Fig. 3 ), reduces RNS, conjugates RES (e.g., quinones), promotes melanin formation, and sequesters radicals within insoluble aggregates ( Fig. 4) . This multimodal redox function is supported three-fold. One, in mice by evidence of sustained oxidative stress in parkin's absence 6, 7 . Two, in humans by complementary findings in ARPD brain ( Fig. 3 ) and the observation of lesser neuromelanin content in surviving DA neurons [27] [28] [29] [30] [51] [52] . We noted with interest that primate-specific residue C95 (located outside of its RING domains) was most frequently found to conjugate DA radicals ( Fig. 4g; Extended Data Fig. 6c ). And three, in parallel work, we discovered a dynamic feedback loop between PRKN expression and glutathione levels in vivo & .
We found that single point mutants have measurable redox effects depending on the experimental context explored ( Fig. 3, 4 ). Such complementary studies will inform clinical genotype-to-phenotype studies in humans 31, 32 . Several reports have shown that point mutation carriers have a later age-of-onset of ARPD than those whose alleles encode no RING domain 31, 32 . The subcellular translocation of parkin (to mitochondria or lysosomes) could be facilitated by oxidation-induced multimer formation at its RING domains ( Fig. 2g,h) . This concept of 'RING scaffolding' has previously been described for other ubiquitin ligases 33 . Because neuronal health and axonal integrity are co-regulated by redox chemistry 34 , we posit that parkin confers its 'inherently present, pro-mitochondrial benefit' 35 via redox homeostasis.
Our study raises new questions. Beyond its localization within LAMP-3 + -lysosomes in DA cells ( Fig. 4i,j) , our results have not yet revealed the fate of oxidized parkin in other neurons. Human LAMP proteins have been shown to store melanin in human keratinocytes to protect them from UV light 22 . Thus, oxidized parkin together with LAMP-3 (and possibly, LAMP-2) could play a similar role in the ongoing storage of neuromelanin and other radicals, thus facilitating their effective sequestration in ageing brain. Of note, the three clones that detect parkin by microscopy seem to preferentially bind to oxidized/aggregated forms in situ. Little anti-parkin signal was detected in midbrain sections from young adults (Extended Data Fig.  8d ), whereas the holoprotein was readily detected by immunoblotting (e.g., Fig. 1a ).
Several limitations were identified. One, although we have detected the PRKN gene to be continuously transcribed in nigral neurons, even at age 99 years ( Fig. 1e) , the rate of its mRNA translation under redox stress conditions, such as during ageing, remains to be studied. Future studies will employ sensitive ELISA-based techniques to quantify the precise concentration of nascent parkin in tissues. Two, we have only begun to map parkin's oxidative modifications that occur in normal human brain (e.g., Extended Data Table 1 ). As highlighted in Extended Data Fig. 3 , parkin likely carries a heterogenous complement of modified cysteine residues in human brain, making the completion of qualitative mapping by LC-MS/MS difficult. Moreover, ROS and RNS modifications can be very transient and thus difficult to capture directly 15, 16, 36 . Three, we have not yet completed a quantitative assessment of oxidative modifications in young vs. old human brain extracts. Future MS studies require further optimization and larger amounts of human tissues including from healthy midbrains. In addition, access to midbrain organoids 37 , such as those generated from entirely parkin-deficient patients and subjects carrying PRKN point mutants, will provide clarification as to which parkin domains are associated with neuromelanin formation.
The strength of this study is that it focused on parkin metabolism in human brain. PRKNlinked ARPD is a human condition, and we are guided by insights from human studies. We posit that parkin fulfils three criteria of an essential redox molecule: the sensing of stressors; structural responses to them; and the participation in corrective measures. If confirmed by future work, this new concept for parkin's function in the human brain opens the door to revisit a possible role in non-PRKN-linked PD and in parkinsonism associated with advanced ageing. It also allows the revisiting of therapeutic approaches in patients afflicted by ARPD, such as through viral vector delivery of PRKN cDNA into parkin-deficient brain 38 and/or by polyvalent, anti-oxidant therapy in select patients 39 .
MATERIALS AND METHODS

Tissue collection
All tissue was collected in accordance with Institutional Review Board-approved guidelines. Fresh frozen samples of cortical human brain from subjects under 50 years of age were acquired through the University of Alabama and the Autism Tissue Program. Post mortem, frozen brain samples from frontal cortices were also obtained from the NICHD Brain and Tissue Bank at the University of Maryland. Brain tissues, including midbrain specimens, with short PMI were also obtained from patients diagnosed with clinical and neuropathological MS according to the revised 2010 McDonald's criteria (n=4) 40 . Tissue samples were collected from MS patients with full ethical approval (BH07.001) and informed consent as approved by the CRCHUM research ethics committee. Autopsy samples were preserved and lesions classified using Luxol Fast Blue / Haematoxylin & Eosin staining and Oil Red O staining as previously published 41, 42 . No inflamed tissue areas were used in this current study. Additional, fresh-frozen and paraffinembedded human samples were obtained from the Neuropathology Service at Brigham and Women's Hospital and from archived autopsy specimens in the Department of Pathology and Laboratory Medicine of The Ottawa Hospital. Human spinal cord and muscle tissues were collected at The Ottawa Hospital with approval from the Ottawa Health Science Network Research Ethics Board.
Wild-type C57Bl/6J mice were used for analysis of the effects of post mortem interval on murine parkin in the brain. Mice from 4 to 8 months old were perfused with PBS and their brains were collected for PMI experiments.
Sequential extraction of parkin from tissue
Roughly 1 cm 3 samples of human brain frontal cortex and midbrain (age range 5-85 years of age) were weighed and placed in 3X volume/weight of Tris Salt buffer (TSS) (5mM Tris, 140 mM NaCl pH 7.5) containing complete EDTA-free protease inhibitor cocktail, and 10 mM iodoacetamide (IAA). The samples were homogenized on ice in a Dounce glass homogenizer by 50 passes, transferred to ultracentrifuge tubes and spun at 55,000 rpm and 4°C for 30 mins. The TS supernatant was transferred to a fresh tube and the pellet was extracted further with addition of 3x volume/weight of Triton X-100 buffer (TX, TS + 2 % Triton X-100). The samples were mixed by vortex, incubated on ice for 10 min and centrifuged again using the same prior setting. The TX supernatant was transferred to a fresh tube and the pellet was extracted further with addition of 3x volume/weight of SDS buffer (SDS, TS + 2 % SDS). The samples were mixed by vortex, incubated at room temperature for 10 min and centrifuged again at 55,000 rpm and 12°C for 30 mins. The SDS supernatant was transferred to a fresh tube and the pellet was either stored at -80°C or extracted further with addition of 3X volume/weight of 6X non-reducing Laemmli buffer (LB, 30 % SDS, 60 % glycerol, 0.3 % bromophenol blue, 0.375 M Tris. pH 6.8, 100mM DTT), mixed by vortex and incubated at room temperature for 10 min. Samples were centrifuged again at 55,000 rpm and 12°C for 30 mins and the LB supernatant was transferred to a fresh tube. Extracted proteins from TS, TXS and SDS buffers including pellet (20-30 µg) and 10-20 µL of LB extracts were run on SDS-PAGE using reducing (100 mM dithiothreitol, DTT) and/or non-reducing (0 mM DTT) loading buffer. Following transfer to membranes, Ponceaus S staining was used to confirm loading, and samples were blotted for parkin (Biolegend 808503, 1: 5,000), DJ-1 (ab18257, 1: 2,000), α-synuclein (syn1 1:1,000 or MJFR1 1:2000), LC3B (3868 1:2000), VDAC (MSA03 1:5000), MnSOD and GLO1 (1:1000), calnexin (MAB3126), cathepsin D (sc-6486), GRP75 (sc-1058) . ImageJ software (1.52 k, National Institutes of Health, USA) was used for signal quantification purposes.
mRNA Analysis
PRKN mRNA isolated from individual S. nigra DA neurons (SNDA), cortical pyramidal neurons (PY) and non-neuronal, blood mononuclear cells (NN) were processed, as described 43 and as annotated in the Human BRAINcode database (www.humanbraincode.org).
ROS (H2O2) measurements
Amplex ® red hydrogen peroxide/peroxidase assay kit (Invitrogen A22188) was used to monitor endogenous levels of H2O2. Pre-weighed cortex pieces from human brains were homogenized on ice in the 1x reaction buffer provided, using a Dounce homogenizer (3 times volume to weight ratio). Homogenates were diluted in the same 1x reaction buffer (10x and 5x). A serial dilution of the H2O2 standard provided was prepared (20, 10, 2 and 0 µM). 50 µL of standards and samples were plated in a 96 well black plate with clear flat bottom. The reaction was started by the addition of 50µL working solution which consist of 1x reaction buffer, Amplex ® red and horseradish peroxidase. The plate was incubated at room temperature for 30 minutes protected from light. A microplate reader was used to measure either fluorescence with excitation at 560 nm and emission at 590 nm, or absorbance at 560 nm. The obtained H2O2 levels (µM) were normalized to the tissue weight (g).
Recombinant protein expression in pET-SUMO vector
Wild-type and truncated (residues 321-465) human parkin were expressed as 6His-Smt3 fusion proteins in Escherichia coli BL21 (DE3) Codon-Plus RIL competent cells (C2527, New England Biolabs) as previous described [44] [45] [46] . DJ-1 and SNCA coding sequences were cloned from a pcDNA3.1 vector into the pET-SUMO vector using PCR and restriction enzymes. ARPDassociated parkin mutants in the pET-SUMO vector were generated using site-directed mutagenesis. All proteins were overexpressed in Escherichia coli BL21 Codon-Plus competent cells (C2527, New England Biolabs) and grown at 37 °C in 2 % Luria Broth containing 30 mg/L kanamycin until OD600 reached 0.6, at which point the temperature was reduced to 16°C. All Parkin-expressing cultures were also supplemented with 0.5 mM ZnCl2. Once OD600 reached 0.8, protein expression was induced with isopropyl β-D-1-thiogalactopyranoside, except ulp1 protease, which was induced once OD600 had reached 1.2. The concentration of IPTG used for each construct is as follows: 25 µM for wild-type and point mutants of parkin, and 0.75 mM for truncated parkin, DJ-1, α-synuclein, SAG, and ulp1 protease. Cultures were left to express protein for 16-20 h. Cells were then harvested, centrifuged, lysed and collected on Ni-NTA agarose beads in elution columns.
Protein redox chemistry and oxidative toxin conjugation
The recombinant protein samples were first prepared by removing excess TCEP, present in the elution buffer using repeat centrifugations (8 times 4000 x g at 4°C for 10 min) in Amicon Ultra 10kDa MWCO filters. The protein concentrations were measured and adjusted to 20µM. Stock solutions of rotenone (1 mM), carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 50 mM), and hydrogen peroxide (H2O2, 9.8 mM) were prepared. Aminochrome was freshly synthesized from Dopamine (see below). An aliquot of 10µL of each protein sample (at 20 µM) was reacted with oxidants at the following concentrations: 0, 10, 20, 200, 2000 µM rotenone; 0, 10, 20, 200 µM CCCP; 0, 2, 20, 50, 200 aminochrome; 0, 20, 200, 500, 750, 1000, 2000 µM H2O2 or 0, 10, 50, 100, 200, 500, 1,000 µM DTT. The samples were treated for 30 min at 37°C and centrifuged at 14,000 rpm for 15 min. The supernatant was transferred to a fresh tube and the remaining pellet was extracted with 10µL of T200-TCEP containing either 10 % SDS or 100 mM DTT. The pellets were incubated again for 30 min at 37°C and centrifuged at 14,000 rpm for 15 min. Laemmli buffer (10 µL, containing 100 mM mercaptoethanol) was added to both the pellet and supernatant fractions and samples were separated on two SDS-PAGE. One gel was used for ingel protein staining and the other was used for NBT staining. Specific bands of aminochrome treated wild-type full length r-parkin were excised from silver-stained gels and analyzed by LC-MS/MS as described below.
Aminochrome synthesis
A solution of 0.1 M sodium phosphate buffer pH 6.0 was prepared from a mixture of 12 mL of 1M NaH2PO4 and 88.0 mL of 1M Na2HPO4. The reaction buffer (0.067 M sodium phosphate, pH 6.0) was prepared by adding 33 mL of 0.1 M sodium phosphate buffer to 17 mL water. A solution of 10mM dopamine in reaction buffer was prepared by adding 19 mg of dopamine hydrochloride to 1 mL of reaction buffer. Oxidation was activated by adding 5 µL of tyrosinase (25,000 U/mL) and the mixture was incubated at room temperature for 5 min. The tyrosinase was separated from the oxidized dopamine using a 50 kDa cut-off Amicon Ultra centrifugation filter by centrifuging at 14,000 rpm for 10 min. The absorbance of the filtrate was measured at a wavelength of 475 nm using Ultrospec 21000 pro spectrophotometer and the concentration of aminochrome was determined using the Beer-Lambert equation and extinction coefficient of 3058 L x mol -1 x cm -1 .
Protein staining methods
All proteins were separated on pre-cast 4-12 % Bis-Tris SDS-PAGE gels (NPO321BOX, NPO322BOX, NPO336BOX) from Invitrogen using MES running buffer (50mM MES, 50mM Tris, 1mM EDTA and 0.1 % SDS, pH 7.3) and Laemmli loading buffer (10% SDS, 20% glycerol, 0.1% bromophenol blue, 0.125M Tris HCl, 200mM DTT or β-mercaptoethanol). Proteins were stained in gel using SilverQuest™ Silver Staining Kit (LC6070) from Invitrogen or Coomassie brilliant blue R-250 dye (20278) from ThermoFisher Scientific using the following protocol: The gel was transferred to a plastic container and rocked for 30 min in Fix Solution (10% acetic acid, 50% methanol), followed by staining for 2-24 h (0.25% Coomassie R250) until the gel turned a uniform blue. The stain was replaced with Destain Solution (7.5% acetic acid and 5% methanol) and the gel was rocked until crisp blue bands appeared. Following a wash with water the gel was stored in 7 % acetic acid. Proteins transferred to PVDF (1620177, Bio-Rad) membranes were stained with Ponceau S solution for 20 min, washed three times with water, imaged and then destained with 0.1M NaOH prior to Western blotting. Proteins conjugated to redox-cycling molecules were stained using the following NBT protocol: Following Ponceau S staining and NaOH destaining, the membrane was washed twice with water, covered from light and incubated with rocking for 45 min in NBT solution [8-9 mg of NBT added to 14 mL of 2 M potassium glycinate buffer (75 g glycine in 0.4 L water and pH adjusted to 10.0 with KOH)]. The membrane was washed twice with destain solution (0.16M sodium borate) and incubated in fresh destain solution for 16-24 h. The membrane was washed once with water and imaged before drying.
Dynamic light scattering (DLS)
The protein buffer (50mM Tris, 200mM NaCl and 250µM TCEP, pH 7.5) was exchanged for a 20mM phosphate buffer with 10mM NaCl (pH 7.4). 20 µM full-length wild-type r-parkin was centrifuged at 14,000 rpm for 60 min at 4 °C and light scattering intensity of the supernatant was collected 30 times at an angle of 90° using a 10 sec acquisition time. Measurements were taken at 37 °C using a Malvern Zetasizer Nano ZS instrument equipped with a thermostat cell. The correlation data was exported and analyzed using the nanoDTS software (Malvern Instruments). The samples were measured at 0-, 1-, 3-and 5 hours. Following 24 hr incubation, 2 mM DTT was added to the sample and the light scattering intensity of the supernatant was measured again.
Far UV circular dichroism spectroscopy 15 µM of reduced and partially oxidized full-length wild-type r-parkin was measured at t = 0 and t = 5 days of incubation under native conditions in 20 mM phosphate, 10 mM NaCl buffer. The aggregates rich phase and the monomer rich phase in the samples were separated with ultracentrifugation (100,000 g for 2 hours). Far UV circular dichroism (CD) spectra were recorded for the monomer and aggregated rich phase of protein samples using a JASCO J-720 spectrometer. The final spectrum was taken as a background-corrected average of 5 scans carried out under the following conditions: wavelength range 250-190 nm at 25 °C; bandwidth was 1 nm; acquisition time was 1 sec and intervals was 0.2 nm. Measurements were performed in a 0.01 cm cell. CD spectra were plotted in mean residue molar ellipticity units (deg cm 2 dmol -1 ) calculated by the following equation: [Θ] = Θobs/(10ncl), where [Θ] is the mean residue molar ellipticity as a function of wavelength, Θobs is the measured ellipticity as a function of wavelength (nm), n is the number of residues in the protein, c is the concentration of the protein (M), and l is the optical path length (cm). Secondary structure analysis of proteins using CD spectroscopic data was carried out using the BeStSel (Beta Structure Selection) software 47, 48 .
Chemiluminescence/ direct reactive oxygen species (ROS) assay
The 
Thiol quantification of recombinant proteins
Recombinant protein samples were first prepared by exchanging the T200 protein buffer (50 mM Tris, 200 mM NaCl and 250 µM TCEP, pH 7.5) for T200-TCEP using repeat centrifugations (8 times 4000 x g at 4°C for 10 min) in Amicon Ultra 10 kDa MWCO filters. The protein concentrations were measured and recorded. The glutathione stock solution of 32,539 µM was prepared by dissolving 1 mg glutathione (GSH) in 1 mL of T200-TCEP and the standards 0, 50, 101, 203, 406, 813 and 1000 µM were prepared by serial dilution in T200-TCEP. The reaction buffer (0.1 M sodium phosphate, pH 8.0) was prepared by adding 93.2 mL 1M Na2HPO4 and 6.8 mL of NaH2PO4 in 1 L of water. Thiol detecting reagent (Ellman's reagent) was prepared by dissolving 2 mg of 5,5'-dithio-bis-[2-nitrobenzoic acid] (DNTB) in 1 mL of reaction buffer. The assay was performed in 96-well clear round bottom plates by adding 50 µL of thiol detecting reagent to 50 µL of sample or standard and incubating for 15 min at room temperature. The resulting 5-thio-2-nitrobenzoic-acid (TNB) produced was measured by absorbance at 412 nm using a Synergy H1Multi-Mode Plate Reader (Bio Tek). The amount of free thiols detected in each sample was calculated using the regression curve obtained from the glutathione standards and dividing by the concentration of the sample.
Cysteine labeling for mass spectrometry
The recombinant protein samples were first prepared by exchanging the T200 buffer for PBS. The protein concentrations were measured and adjusted to 10 µM using PBS. Stock solutions of 500 mM DTT, 100 mM iodoacetamide (IAA), 100 mM hydrogen peroxide and 250 mM ethylenediaminetetraacetic acid (EDTA) were prepared in PBS. A stock of 500 mM N-ethylmaleimide (NEM) was prepared in ethanol immediately before use. For the first optimization and comparison of IAA and NEM labelling (i.e., Table S2 ), r-parkin was treated with 2 mM DTT for 30 min at 37°C followed by incubation with 5 mM IAA or 85 mM NEM for 2 h at 37°C. The stepwise cysteine labeling procedure was as follows: A 10 µL aliquot of protein (at 10 µM) was reacted with hydrogen peroxide at various concentrations, as indicated (Table 1) for 30 min (and up to 60 min) at 37°C as indicated. Any unreacted cysteines were alkylated with incubation with 5 mM IAA (either with or, in some runs, without 10 mM EDTA) for 2 hrs at 37°C. Previously oxidized cysteines were then reduced by treatment with 40 mM DTT for 30 min at 37°C. Newly reduced cysteines were alkylated by incubation with 85 mM N-ethyl maleimide (NEM) for 2 hrs at 37°C. The samples were separated on SDS-PAGE using Laemmli buffer containing 100 mM DTT and proteins visualized using Coomassie staining. Appropriate bands were excised and analyzed by liquid chromatography mass spectrometry (LC-MS/MS).
Protein identification by LC-MS/MS
Proteomics analysis was performed at the Ottawa Hospital Research Institute Proteomics Core Facility (Ottawa, Canada). Proteins were digested in-gel using trypsin (Promega) according to the method of Shevchenko 49 . Peptide extracts were concentrated by Vacufuge (Eppendorf). LC-MS/MS was performed using a Dionex Ultimate 3000 RLSC nano HPLC (Thermo Scientific) and Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific). MASCOT software version 2.6.2 (Matrix Science, UK) was used to infer peptide and protein identities from the mass spectra. For detection of dopamine metabolites on Parkin, the following variable modifications were included: 5,6-indolequinone (+C8O2NH3, m/z shift +145), aminochrome (+C8O2NH5, +147), aminochrome +2H (+C8O2NH7, +149), and dopamine quinone (+C8O2NH9, +151). These samples were prepared for analysis without any use of dithiothreitol or iodoacetamide. The observed spectra were matched against human sequences from SwissProt (version 2018-05) and also against an in-house database of common contaminants. The results were exported to Scaffold (Proteome Software, USA) for further validation and viewing. Analysis of the holoprotein and of three runs of H2O2-exposed r-parkin (Supplemental Table 2 ) were performed at the University of Western Ontario. There, samples were run on a QToF Ultima mass spectrometer (Waters) equipped with a Z-spray source and run in positive ion mode with an Agilent 1100 HPLC used for LC gradient delivery (University of Western Proteomics Facility).
MaxQuant analysis of mass spectrometry data
For applicable experiments, the raw MS data files were further processed with MaxQuant software version 1.6.5 and searched with the Andromeda search engine 18 . The reference fastas were set to uniprot-human (version 2019-02-12) and uniport-ecoli. The E. coli proteome was included to account for bacterial proteins present in the recombinant protein samples. The 'second peptides' and 'match between runs' settings were enabled. All other settings were left as default. Selected variable modifications included oxidation (Met), acetylation (protein Nterminus), and carbamidomethyl (Cys), as well as custom modifications for pyrocarbamidomethyl (N-terminal Cys), N-ethylmaleimide (Cys), and NEM+water (Cys). For data analysis, site-level intensity values were obtained from the MaxQuant-generated "CarbamidomethylSites" table which combines the intensity of MS1 signals from all peptides covering a particular cysteine residue.
Immunoprecipitation (IP) of brain parkin
Conjugation of anti-parkin antibody (Prk8, 808503, lot B209868) to magnetic beads at a final concentration of 10 mg of antibody/ mL of beads was done following the Magnetic Dynabeads Antibody Coupling Kit from Invitrogen (14311D). Human tissue lysates were also prepared using the "Sequential Extraction of Proteins from Tissue" protocol as described above with addition of 10 mM iodoacetamide prior to homogenization. TS tissue extracts (n=4) and SDS tissue extracts (n=8) were diluted in TS buffer, resulting in a final SDS concentration of 0.0175 % and 0.05 % respectively. For the IP, Prk8 conjugated agarose beads were first prepared by multiple washes with 1 mL of TS buffer using centrifugation (1000 x g at 4°C for 3 min) and adhesion to a strong magnet. Amounts of Prk8 conjugated agarose beads used for each experiment were approximated based on the amount of parkin (µg) / sample calculated by densitometry when the sample was compared to recombinant parkin protein standards using Western blotting with Prk8 primary antibody. The mixture was incubated for 16 h at 4°C with slow rotation. Unbound proteins, which did not bind to the Prk8 conjugated agarose beads, were separated from the beads by centrifugation (1000 x g at 4°C for 3 min) followed by adhesion to a strong magnet and saved as the IP "unbound" fraction. Beads from cellular or human IP were washed three times with 900 or 1000 µL respectively of ice-cold RIPA buffer (1 % nonionic polyoxyethylene-40, 0.1 % SDS, 50 mM Tris, 150 mM NaCl, 0.5 % sodium deoxycholate, 1 mM EDTA) using centrifugation (1000 x g at 4°C for 3 min) and adhesion to a strong magnet. Approximately 5-10 µL of each wash was combined and saved as the IP "wash" fraction. To elute Prk8 bound proteins, 15-35 uL of 6X reducing Laemmli buffer (30 % SDS, 60 % glycerol, 0.3 % bromophenol blue, 0.375 M Tris, 100 mM DTT, pH 6.8) was added to the beads and the samples were boiled for 5 min. Following centrifugation (1000 x g at 4°C for 3 min), the supernatant was transferred to a fresh tube labeled "IP elute" and the beads were discarded. To assess IP efficiency, eluted fractions (IP elute), along with controls (input, unbound, wash and recombinant parkin protein standards) were run on SDS/PAGE and blotted with anti-parkin (MAB5512 or 2132S). Human IP elutes used in subsequent for mass spectrometry (MS) analysis were incubated with 500 mM N-ethyl maleimide (as indicated for select runs) for 16 h at 4°C prior to SDS-PAGE and further processing for MS (as described above). Gel slices corresponding to band sizes 50-75 kDa were excised and analyzed by LC-MS/MS.
In vitro melanin formation assay
The recombinant protein samples were first prepared by exchanging the T200 protein buffer (50 mM Tris, 200 mM NaCl and 250 µM TCEP, pH 7.5) for T200-TCEP (50 mM Tris and 200 mM NaCl, pH 7.5) using repeat centrifugations (8 times 4000 x g at 4°C for 10 min) in Amicon Ultra 10 kDa MWCO filters. The protein concentrations were measured and adjusted to 20 µM using T200-TCEP. A 0.067 M sodium phosphate buffer, pH 6.0, was prepared by adding 33 mL of 0.1 M sodium phosphate buffer to 17 mL water and adjusting the pH using HCl. A stock solution of 100 mM dopamine HCl was prepared in 0.067 M sodium phosphate buffer and stock solutions of 100 mM reduced glutathione (GSH) and hydrogen peroxide were prepared in T200-TCEP.
Samples and controls were prepared in 100 µL total volume and contained: 10 µL of 20 µM protein or T200-TCEP, 10 µL of 100 mM dopamine or 0.067 M sodium phosphate buffer, 10 µL of 100 mM glutathione or T200-TCEP buffer, and 70 µL T200-TCEP. The final concentration of protein was 2 µM and the final concentration of reagents was all 10 mM. The samples and controls were plated in triplicate, and absorbance read at 405 and 475 nm every 90 sec for 1 h. The plate was then protected from light and incubated for 24 h. A final reading of absorbance at 405 and 475 nm was taken after 24 h. Dopamine hydrochloride (Sigma H8502) 200 mM stock was prepared. The cells were washed with fresh media once and then incubated with media alone or supplemented with dopamine at final concentrations of 20 µM and 200 µM for 18-20 hours. Post dopamine stress, media was collected from all wells for cytotoxicity assay, the cells were harvested and lysed with TS buffer and centrifuged. The supernatant was collected and saved for western blot analysis and to assess total cell toxicity signal. The pellet was suspended in SDS buffer and centrifuged.
Cell cytotoxicity assay
Vybrant TM cytotoxicity assay kit (Molecular Probes V-23111) was used to monitor cell death through the release of the cytosolic enzyme glucose 6-phosphate dehydrogenase (G6yPD) from damaged cells into the surrounding medium. 50 µl of media alone (no cells), media from control and stressed cells and cell lysates were added to a 96-well microplate. Fifty µl of reaction mixture, containing reaction buffer, reaction mixture and resazurin, was added to all wells, and the mircroplate was incubated at 37°C for 30 mins. A microplate reader was used to measure either fluorescence with excitation at 560 nm and emission at 590 nm. A rise in fluoresence indicates a rise in G6PD levels i.e. a rise in cell death.
Immunohistochemistry (IHC)
Immunohistochemistry was performed on paraffin-embedded sections and treated as previously described (Schlossmacher et al. 2002; Schlossmacher and Shimura 2005, Shutinoski et al 2019) . Briefly, prior to antibody incubation, sections were deparaffinized in xylene and successively rehydrated through a series of decreasing ethanol concentration solutions. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide in methanol, followed by a standard citric acid-based antigen retrieval protocol to unmask epitopes. Sections were blocked in 10-20% serum in PBS-T to reduce non-specific signal. Sections were incubated overnight at 4°C in primary antibodies diluted in 1-5% serum in PBS-T according to the following concentrations: novel Parkin mAbs from Biolegend clones D (BioLegend, A15165D; 1:250), clone E (BioLegend, A15165E; 1:2000), and clone G (1:250), PRK8 (BioLegend, MAB5512; 1:500), Lamp3 (Santa Cruz, SC5275; 1:100), LC3B (Sigma, L7543-200uL; 1:100), VDAC (MitoScience, MSA03; 1:100). Biotinylated secondary antibodies (biotinylated anti mouse IgG (H+L) made in goat; Vector Labs, BA-9200, biotinylated anti-rabbit IgG (H+L) made in goat; Vector Labs, BA-1000) were diluted to 1:225 and sections were incubated for 2 hours at room temperature. The signal was amplified with VECTASTAIN® Elite® ABC HRP Kit (Vector Labs, PK-6100), and visualized via standard DAB solution, 55mM DAB, or Vina green (Biocare Medical, BRR807AH), or most commonly metal enhanced DAB (Sigma, SIGMAFAST™ DAB with Metal Enhancer D0426). Samples were counterstained with Harris Modified Hematoxylin nuclei stain and dehydrated through a series of increasing ethanol concentration solutions and xylene. Permount (Fisher Scientific, SP15-100) was used for mounting and slides were visualized with high magnification images via a Quorum Slide Scanner (Ottawa Hospital Research Institute).
Immunofluorescence (IF) and confocal microscopy
Paraffin-embedded human midbrain sections were stained by routine indirect immunofluorescence with the following details. Antigen retrieval was performed in Tris-EDTA buffer pH 9 for 10 mins. Primary antibodies were incubated overnight at 4C. Details for primary antibodies anti-Parkin Clone E (1:500), anti-LAMP3 (1:250) are described above. A 40 minute incubation with the following secondary antibodies was performed: goat anti-mouse alexa fluor 488 (1:200), goat anti-rabbit alexa fluor 594 (1:500). Slides were mounted with fluorescence mounting medium with DAPI. Stained sections were imaged using a Zeiss LSM 880 AxioObserver Z1 with an Airyscan Confocal Microscope then processed and analyzed using Zeiss Zen and Fiji software.
Statistical analyses
All statistical analyses were performed using GraphPad Prism version 6 (GraphPad Software, San Diego, CA, USA, www.graphpad.com). Differences between two groups were assessed using an unpaired t-test. Differences among 3 or more groups were assessed using a one-way or two-way ANOVA followed by Tukey's post hoc corrections to identify statistical significance. Subsequent post hoc tests are depicted graphically and show significance between treatments. Fig. 4h (r-parkin) . Fig. 2a .
(e-f) Circular dichroism spectra of soluble, H 2 O 2 -exposed WT r-parkin secondary structure at (e) T=0 and (f) soluble (black line) and aggregated (red line) states following incubation at 37 o C for T=5 days to promote spontaneous oxidation as described in Fig. 2c,d Extended Data Figure 6 . Parkin conjugates dopamine metabolites at C95 (a) Western blot analysis of ectopic, WT and mutant parkin expression in dopamine-treated M17 cells, as described in Fig. 4a,b.  (b) In vitro melanin formation, as monitored by a colorimetric assay (absorbance rate, 405nm) demonstrating increased polymerization of dopamine (DA) over a 60 min period in the presence or absence (blank) of wild-type (WT) r-parkin and two point mutants (G328E; C431F). Melanin synthesis from dopamine is blocked in the presence of glutathione (GSH). Data represent the mean of triplicates ± SEM. ***p<0.05 by 1-way ANOVA. (a-c) Characterization of four murine, monoclonal antibodies (of IgG 2 isotype; clone-B, -E, -D, and -G) in three different assays: (a) against recombinant (r-), full-length, untagged, wildtype (WT) human parkin using non-denaturing slot blots (100ng/slot) of original antigen as well as truncated r-parkin 321-465 and full-length, untagged, human r-DJ-1; (b) against human brain lysates (SDS fractions from control and PRKN-linked ARPD cases) using non-denaturing dot blots; and (c) by denaturing SDS/PAGE and Western blotting of extracts from cortical specimens of a control brain and a parkin-deficient ARPD case. Screening by these three methods as well as by cell-based microscopy (using indirect immunofluorescence) revealed specific staining for four anti-parkin clones (-B, -E, -D and -G), which was conformation-dependent for clone-E. (d) List of epitopes within the sequence of human parkin, as recognized by clones -B, -E, -D, and -G and informed by overlapping screening with 7-12 amino acid-long peptides covering full-length, human parkin. Note that the clone E epitope is conformational, comprised of the three regions indicated.
